These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
84. Real-Life Experience with Aflibercept and Ranibizumab in the Treatment of Newly Diagnosed Neovascular Age-Related Macular Degeneration over 24 Months. Garweg JG; Gerhardt C; Kodjikian L; Pfister IB J Ocul Pharmacol Ther; 2017 Sep; 33(7):567-572. PubMed ID: 28557667 [TBL] [Abstract][Full Text] [Related]
85. Response to aflibercept after frequent re-treatment with bevacizumab or ranibizumab in eyes with neovascular AMD. Thorell MR; Nunes RP; Chen GW; Doshi RR; Dugar J; George MK; Kim BT; Lowrance MD; Modi D; Nahas Z; Gregori G; Yehoshua Z; Feuer W; Rosenfeld PJ Ophthalmic Surg Lasers Imaging Retina; 2014; 45(6):526-33. PubMed ID: 25423632 [TBL] [Abstract][Full Text] [Related]
86. Efficacy and adverse events of aflibercept, ranibizumab and bevacizumab in age-related macular degeneration: a trade-off analysis. Schmid MK; Bachmann LM; Fäs L; Kessels AG; Job OM; Thiel MA Br J Ophthalmol; 2015 Feb; 99(2):141-6. PubMed ID: 25271911 [TBL] [Abstract][Full Text] [Related]
87. Competition law and pricing among biologic drugs: the case of VEGF therapy for retinal diseases. Van de Wiele VL; Hammer M; Parikh R; Feldman WB; Sarpatwari A; Kesselheim AS J Law Biosci; 2022; 9(1):lsac001. PubMed ID: 35211322 [TBL] [Abstract][Full Text] [Related]
88. Future of anti-VEGF: biosimilars and biobetters. Kapur M; Nirula S; Naik MP Int J Retina Vitreous; 2022 Jan; 8(1):2. PubMed ID: 34983660 [TBL] [Abstract][Full Text] [Related]
89. Neovascular Age-Related Macular Degeneration (nAMD): A Review of Emerging Treatment Options. Tan CS; Ngo WK; Chay IW; Ting DS; Sadda SR Clin Ophthalmol; 2022; 16():917-933. PubMed ID: 35368240 [TBL] [Abstract][Full Text] [Related]
90. Safety of recent ophthalmic drugs and devices for wet macular degeneration. Timtim E; Weng CY; Finn AP Curr Opin Ophthalmol; 2023 Sep; 34(5):363-368. PubMed ID: 37326230 [TBL] [Abstract][Full Text] [Related]
91. Difficulty in Assessing the Systemic Adverse Effects of Intravitreal Anti-Vascular Endothelial Growth Factor Therapy. VanderBeek BL JAMA Ophthalmol; 2023 Jul; 141(7):666-667. PubMed ID: 37261809 [No Abstract] [Full Text] [Related]
92. Cognitive bias evaluation on the choice of treatment in common retinal disorders among retina specialists in 2023. Niegowski LJ; Cohen SY; Crincoli E; Mehanna CJ; Souied EH J Fr Ophtalmol; 2024 Jun; 47(6):104177. PubMed ID: 38603895 [TBL] [Abstract][Full Text] [Related]
93. Novel and investigational therapies for wet and dry age-related macular degeneration. Sarkar A; Jayesh Sodha S; Junnuthula V; Kolimi P; Dyawanapelly S Drug Discov Today; 2022 Aug; 27(8):2322-2332. PubMed ID: 35460893 [TBL] [Abstract][Full Text] [Related]
95. In vitro and in ovo experimental study of two anti-VEGF agents used in ophthalmology. Palfi MC; Muşat O; Şeclăman EP; Munteanu M; Milcu AI; Iordache A; Dolghi A; Istrate SL; Barac IR; Borugă VM Rom J Morphol Embryol; 2021; 62(3):801-806. PubMed ID: 35263409 [TBL] [Abstract][Full Text] [Related]
97. Biosimilar Ranibizumab (SB11) vs Reference Ranibizumab-Diving Deeper for Safety and Efficacy. Sharma A; Kumar N; Parachuri N JAMA Ophthalmol; 2021 Jun; 139(6):677-679. PubMed ID: 33914017 [No Abstract] [Full Text] [Related]
98. Biosimilar Ranibizumab (SB11) vs Reference Ranibizumab-Diving Deeper for Safety and Efficacy-Reply. Bressler NM JAMA Ophthalmol; 2021 Jun; 139(6):678-679. PubMed ID: 33914021 [No Abstract] [Full Text] [Related]
99. Production of a biosimilar version of aflibercept to improve VEGF blocker cytotoxicity on endothelial cells. Ramezani A; Zareinejad M; Mahmoudi Maymand E; Kaviani E; Ghaderi A Growth Factors; 2023 Aug; 41(3):140-151. PubMed ID: 37377438 [TBL] [Abstract][Full Text] [Related]